Therefore, we hypothesized that LOFU-mediated immune priming of tumors, followed by ablative RT should increase the release of tumor-derived HSP-peptide complexes that could promote antigen cross-presentation and activation of CD8+ T cells for the induction of systemic anti-tumoral immunity. The gene discussed is CD8A; the disease is neoplasm.